Abstract:Clinical Trials, Ahead of Print. Background/Aims:Multi-arm, multi-stage trials frequently include a standard care to which all interventions are compared. This may increase costs and hinders comparisons among the experimental arms. Furthermore, the standard care may not be evident, particularly when there is a large variation in standard practice. Thus, we aimed to develop an adaptive clinical trial that drops ineffective interventions following an interim analysis before selecting the best intervention at the final stage without requiring a standard care.Methods:We used Bayesian methods to develop a multi-arm, two-stage adaptive trial and evaluated two different methods for ranking interventions, the probability that each intervention was optimal (Pbest) and using the surface under the cumulative ranking curve (SUCRA), at both the interim and final analysis. The proposed trial design determines the maximum sample size for each intervention using the Average Length Criteria. The interim analysis takes place at approximately half the pre-specified maximum sample size and aims to drop interventions for futility if either Pbest or the SUCRA is below a pre-specified threshold. The final analysis compares all remaining interventions at the maximum sample size to conclude superiority based on either Pbest or the SUCRA. The two ranking methods were compared across 12 scenarios that vary the number of interventions and the assumed differences between the interventions. The thresholds for futility and superiority were chosen to control type 1 error, and then the predictive power and expected sample size were evaluated across scenarios. A trial comparing three interventions that aim to reduce anxiety for children undergoing a laceration repair in the emergency department was then designed, known as the Anxiolysis for Laceration Repair in Children Trial (ALICE) trial.Results:As the number of interventions increases, the SUCRA results in a higher predictive power compared with Pbest. Using Pbest results in a lower expected sample size when there is an effective intervention. Using the Average Length Criterion, the ALICE trial has a maximum sample size for each arm of 100 patients. This sample size results in a 86% and 85% predictive power using Pbest and the SUCRA, respectively. Thus, we chose Pbest as the ranking method for the ALICE trial.Conclusion:Bayesian ranking methods can be used in multi-arm, multi-stage trials with no clear control intervention. When more interventions are included, the SUCRA results in a higher power than Pbest. Future work should consider whether other ranking methods may also be relevant for clinical trial design.

A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data

A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Effects of Allocation Method and Time Trends on Identification of the Best Arm in Multi-Arm Trials

Comparison of response adaptive randomization features in multiarm clinical trials with control

Bayesian Optimal Phase II Design for Randomized Clinical Trials

A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies

Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials

A Novel Statistical Test for Treatment Differences in Clinical Trials using a Response Adaptive Forward Looking Gittins Index Rule

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints

A framework for testing non-inferiority in a three-arm, sequential, multiple assignment randomized trial

Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials

Optimality of testing procedures for survival data

An optimised multi-arm multi-stage clinical trial design for unknown variance

A comparison of alternative ranking methods in two-stage clinical trials with multiple interventions: An application to the anxiolysis for laceration repair in children trial

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers